METRICS NAMES DIRECTOR OF MANUFACTURING OPERATIONS

METRICS NAMES DIRECTOR OF MANUFACTURING OPERATIONS
Appointment emphasizes collaboration between formulation development and manufacturing
GREENVILLE, N.C. - Metrics Inc. has appointed W. David Varley as director of manufacturing operations.

Since its start in 1994, Metrics Inc. has evolved from a start-up analytical laboratory into one of the fastest-growing contract pharmaceutical development and manufacturing organizations in the United States. The company is highly regarded for collaborative internal processes that help pharmaceutical clients formulate critical compounds and gradually scale them up to commercial manufacturing.

"That's one of the many corporate strengths that attracted me to Metrics," Varley said. "We really do maintain a close level of contact that eliminates many of the problems clients experience when they scale up production at other facilities."

Varley brings to Metrics nearly 30 years of pharmaceutical manufacturing and packaging experience gained with companies such as Burroughs Wellcome, Glaxo Wellcome, E.R. Squibb and Purdue Pharmaceuticals. Prior to joining Metrics, Varley was director of manufacturing for Bio Delivery Sciences International.

Headquartered in Greenville, N.C., Metrics provides quality pharmaceutical formulation development; first-time-in-man formulations; clinical material manufacturing for Phase I, II and III trials; commercial manufacturing; and analytical method development and validation services to the pharmaceutical industry.

Metrics offers the latest development and analytical equipment housed within a state-of-the-art, 92,000-square-foot cGMP facility. Facilities include a dedicated potent products suite; seven analytical laboratories; seven pharmaceutical development suites; seven large-scale manufacturing and packaging rooms for Phase III clinical trial and commercial manufacturing; stability storage; and a microbiology laboratory.

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.